latest news releases from the newsroom
Miniter Group Successfully Maintains Operations During Winter Storm Juno
NORWELL, Mass., Jan. 30, 2015 (GLOBE NEWSWIRE) -- via PRWEB - Miniter Group today announced that it was successfully able to maintain operations during Winter Storm Juno. The storm left Miniter's Norwell employees unable to travel to the office on Tuesday January 27th due to a state wide transportation ban. The Norwell office lost power at 8:01 AM on Tuesday, auxiliary power had the Norwell office back on line 8 seconds later and there was no interruption of network services. Miniter's insurance tracking system continued to operate and there was no interruption of compliant letter cycles, insurance placements or cancellations for force placed insurance. Regular operations were able to continue by Noon on Wednesday January 28th.
Brower Piven, A Professional Corporation
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in InvenSense, Inc. to Contact Brower Piven Before the March 9, 2015 Lead Plaintiff Deadline in Class Action Lawsuit -- INVN
STEVENSON, Md., Jan. 30, 2015 (GLOBE NEWSWIRE) -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf of purchasers of InvenSense, Inc. ("InvenSense" or the "Company") (NYSE:INVN) common stock during the period between July 29, 2014 and October 28, 2014, inclusive (the "Class Period"). Investors who wish to become proactively involved in the litigation have until March 9, 2015 to seek appointment as lead plaintiff.
Zogenix Receives FDA Approval of New Formulation of Zohydro(R) ER
SAN DIEGO, Jan. 30, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has approved a new formulation of Zohydro
Chimerix Focusing Efforts on CMV and Adenovirus Pivotal Trials
DURHAM, N.C., Jan. 30, 2015 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced that after discussion with the U.S. Food and Drug Administration, the company is ceasing further participation in all current and future clinical studies of brincidofovir for Ebola Virus Disease (EVD), including the study announced in December in Liberia sponsored by investigators at the University of Oxford and the supportive Phase 2 study of brincidofovir for EVD, Study 205.